ADMA Biologics Inc (ADMA) has disclosed a new risk, in the Regulation category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ADMA Biologics Inc. faces significant business risks that could impact its stock value, as highlighted in their quarterly report. The summary of risk factors indicates that investing in their common stock is speculative due to various principal factors. These risks are detailed further in the report under ‘Risk Factors’ and should be reviewed alongside other information provided. Investors are advised to carefully consider these risks before making investment decisions.
Overall, Wall Street has a Moderate Buy consensus rating on ADMA stock based on 2 Buys.
To learn more about ADMA Biologics Inc’s risk factors, click here.